UNSPSC 51433804: Levosimendan

This classification denotes an anti-arrhythmia agent, cardiotonic agent, and vasodilator agent with the molecular formula C14H12N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C6T4514L4E, chemically known as (r)-((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile but generally known as levosimendan, which bears US NIH Compound Identifier 3033825. European Medicines Agency schedules Levosimendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08493MIG.

World Health Organization schedules levosimendan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levosimendan under HS 29339990 and SITC 51577. As of Q4 2014, LEVOSIMENDAN remains the US FDA Preferred Term for this commodity. SMILES: O=C1NN=C(C(C1)C)c1ccc(N/N=C(/C#N)C#N)cc1.

UNSPSC 51433804 Levosimendan is a Commodity code representing advanced life support medications and related pharmaceutical products procured by state and local health and emergency services agencies. State and local governments buy specific injectable medications under this code — epinephrine, adenosine, labetalol, diltiazem, and related acute-care pharmaceuticals — for use by fire rescue departments, emergency medical services, and health and human services agencies. Issuing bodies include city purchasing departments acting on behalf of fire rescue operations, state health agencies managing pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating procurement across multiple jurisdictions. The work involves sourcing FDA-compliant medications with strict expiration-date requirements, maintaining wholesaler relationships and supply-chain compliance documentation (cGMP, DSCSA), managing chargeback systems, and delivering products within defined timeframes to emergency and clinical settings.

Activity under the code spans at least three states: Florida (City of Tampa, Hillsborough County), Texas (Texas Health and Human Services Commission), and Minnesota (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with a due date of April 8, 2026, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a 5 percent SLBE bid discount available. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802) with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers and targeting July 1, 2026 contract effectiveness. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling emerging state interest in alternative pharmaceutical supply-chain models.